Contemporary Management of Nonfunctioning Pancreatic Neuroendocrine Tumors

Journal of Gastrointestinal Surgery

Volumn 16, Issue 2, 2012, Pages 435-446

  Minter, Rebecca M ^a   Simeone, Diane M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Neuroendocrine tumor; NF PNET; Nonfunctioning; Pancreas; Pancreatic

Indexed keywords

TUMOR MARKER;

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPIC ECHOGRAPHY; HEALTH SURVEY; HUMAN; LIVER TRANSPLANTATION; METABOLISM; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PROGNOSIS; REVIEW;

ENDOSONOGRAPHY; HUMANS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POPULATION SURVEILLANCE; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84856233519     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1693-5     Document Type: Review

References (75)

1. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135: 1469-1492.
2. Falconi M, Plockinger U, Kwekkeboom DJ et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006; 84: 196-211.
3. Ito T, Tanaka M, Sasano H et al. Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 2007; 42: 497-500.
4. Panzuto F, Nasoni S, Falconi M et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12: 1083-1092.
5. Kloppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 15-31.
6. Pais SA, Al-Haddad M, Mohamadnejad M et al. EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience. Gastrointest Endosc 2010; 71: 1185-1193.
7. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008; 113: 1807-1843.
8. Kulke MH, Siu LL, Tepper JE et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011; 29: 934-943.
9. Rindi G, Kloppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401.
10. Ekeblad S, Skogseid B, Dunder K et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14: 7798-7803.
11. La Rosa S, Sessa F, Capella C et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 1996; 429: 323-333.
12. Jensen RT. Natural history of digestive endocrine tumors. Paris, France: John Libbey Eurotext Publishing Co. 1999.
13. Madeira I, Terris B, Voss M et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998; 43: 422-427.
14. Chu QD, Hill HC, Douglass HO, Jr. et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002; 9: 855-862.
15. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000; 62 Suppl 1: 51-58.
16. Que FG, Sarmiento JM, Nagorney DM. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Cancer Control 2002; 9: 67-79.
17. Blansfield JA, Choyke L, Morita SY et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 2007; 142: 814-818; discussion 818 e811-812.
18. O'Toole D, Grossman A, Gross D et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 2009; 90: 194-202.
19. Oberg K, Stridsberg M. Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. Adv Exp Med Biol 2000; 482: 329-337.
20. Panzuto F, Severi C, Cannizzaro R et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 2004; 27: 6-11.
21. Sundin A, Vullierme MP, Kaltsas G, Plockinger U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90: 167-183.
22. Akerstrom G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 87-109.
23. Diehl DL, Blansfield J, Li J. Cystic pancreatic neuroendocrine tumor. Gastrointest Endosc 2010; 71: 1064-1065; discussion 1065.
24. Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 69-85.
25. Lebtahi R, Cadiot G, Sarda L et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997; 38: 853-858.
26. Alexander HR, Fraker DL, Norton JA et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228: 228-238.
27. Hellman P, Andersson M, Rastad J et al. Surgical strategy for large or malignant endocrine pancreatic tumors. World J Surg 2000; 24: 1353-1360.
28. Norton JA, Kivlen M, Li M et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003; 138: 859-866.
29. Evans DB, Skibber JM, Lee JE et al. Nonfunctioning islet cell carcinoma of the pancreas. Surgery 1993; 114: 1175-1181; discussion 1181-1172.
30. Solorzano CC, Lee JE, Pisters PW et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001; 130: 1078-1085.
31. Warshaw AL, Rattner DW, Fernandez-del Castillo C, Z'Graggen K. Middle segment pancreatectomy: a novel technique for conserving pancreatic tissue. Arch Surg 1998; 133: 327-331.
32. Yamaguchi K, Yokohata K, Ohkido M et al. Which is less invasive-distal pancreatectomy or segmental resection? Int Surg 2000; 85: 297-302.
33. Sellner F, Thalhammer S, Stattner S et al. TNM stage and grade in predicting the prognosis of operated, non-functioning neuroendocrine carcinoma of the pancreas-a single-institution experience. J Surg Oncol 2011.
34. Touzios JG, Kiely JM, Pitt SC et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005; 241: 776-783; discussion 783-775.
35. Chamberlain RS, Canes D, Brown KT et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190: 432-445.
36. Kulke MH, Anthony LB, Bushnell DL et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010; 39: 735-752.
37. Sakurai A, Katai M, Yamashita K et al. Long-term follow-up of patients with multiple endocrine neoplasia type 1. Endocr J 2007; 54: 295-302.
38. Triponez F, Goudet P, Dosseh D et al. Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 2006; 30: 654-662; discussion 663-654.
39. Triponez F, Cadiot G. Non-functioning tumours of the pancreas in MEN1 patients. J Gastrointestin Liver Dis 2007; 16: 295-296.
40. Gauger PG, Scheiman JM, Wamsteker EJ et al. Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1. Br J Surg 2003; 90: 748-754.
41. Langer P, Kann PH, Fendrich V et al. Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg 2004; 28: 1317-1322.
42. Thomas-Marques L, Murat A, Delemer B et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 2006; 101: 266-273.
43. Kouvaraki MA, Shapiro SE, Cote GJ et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 2006; 30: 643-653.
44. Hammel PR, Vilgrain V, Terris B et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000; 119: 1087-1095.
45. Libutti SK, Choyke PL, Bartlett DL et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery 1998; 124: 1153-1159.
46. Maddock IR, Moran A, Maher ER et al. A genetic register for von Hippel-Lindau disease. J Med Genet 1996; 33: 120-127.
47. Rosenau J, Bahr MJ, von Wasielewski R et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 2002; 73: 386-394.
48. Le Treut YP, Gregoire E, Belghiti J et al. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant 2008; 8: 1205-1213.
49. O'Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19: 585-594.
50. Toumpanakis C, Meyer T, Caplin ME. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 131-144.
51. Yao KA, Talamonti MS, Nemcek A et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001; 130: 677-682; discussion 682-675.
52. Kennedy AS, Dezarn WA, McNeillie P et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31: 271-279.
53. King J, Quinn R, Glenn DM et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113: 921-929.
54. Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005; 30: 435-441.
55. Forrer F, Valkema R, Kwekkeboom DJ et al. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007; 21: 111-129.
56. Kwekkeboom DJ, de Herder WW, Kam BL et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.
57. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
58. Tuveson D, Hanahan D. Translational medicine: cancer lessons from mice to humans. Nature 2011; 471: 316-317.
59. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
60. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
61. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.
62. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
63. Chiu CW, Nozawa H, Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol 2010; 28: 4425-4433.
64. Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199-1203.
65. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005; 19: 753-781.
66. Faiss S, Pape UF, Bohmig M et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689-2696.
67. Kouvaraki MA, Ajani JA, Hoff P et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22: 4762-4771.
68. Pavel ME, Baum U, Hahn EG, Hensen J. Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors. Int J Gastrointest Cancer 2005; 35: 179-185.
69. Ramanathan RK, Cnaan A, Hahn RG et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001; 12: 1139-1143.
70. Strosberg JR, Fine RL, Choi J et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275.
71. Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006; 24: 3548-3554.
72. Steinmuller T, Kianmanesh R, Falconi M et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008; 87: 47-62.
73. Chan JA, Kulke MH. Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. Expert Opin Emerg Drugs 2007; 12: 253-270.
74. Strosberg JR, Kvols LK. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 2007; 16: 219-224.
75. Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. Hematol Oncol Clin North Am 2007; 21: 575-581; x.